Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -53.96 | -38.02 | -24.69 | |
| Graham Fair Price | -3.08 | 10.24 | 10.57 | |
| PEG | -35.88 | 0.97 | -1.51 | |
| Price/Book | 94.10 | 7.70 | 3.97 | |
| Price/Cash Flow | -40.27 | -44.50 | -31.72 | |
| Prices/Earnings | -51.06 | -10.27 | -6.80 | |
| Price/Sales | 204.75 | 2728.73 | 895.39 | |
| Price/FCF | -40.27 | -44.50 | -31.72 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -25.25 | 0.57 | 0.76 | |
| Operating Margin | -114.44 | -72.05 | -33.60 | |
| ROA | -23.78 | -0.14 | -0.11 | |
| ROE | -0.15 | -0.19 | -28.49 | |
| ROIC | -0.13 | -0.17 | -27.98 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.11 | -0.03 | -274.03 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.03 | -0.18 | -623.02 | |
| EPS QOQ | 0.04 | -0.11 | 135.59 | |
| FCF QOQ | -0.38 | -0.20 | 47.25 | |
| Revenue QOQ | 2.57 | -0.45 | -82.55 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 488.00 | 1123.24 | 130.17 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.08 | 0.09 | 2.36 | |
| Quick Ratio | 6.92 | 5.72 | -17.34 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q1 | Q2 | Δ in % | |
|---|---|---|---|---|
| Book Value | 5.83 | 4.99 | -14.50 | |
| Cash | 4.96 | 4.15 | -16.24 | |
| Capex | -0.01 | < 0.005 | 34.05 | |
| Free Cash Flow | -0.73 | -0.86 | -18.32 | |
| Revenue | 0.03 | 0.01 | -45.54 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad